Ondine Biomedical celebrates regulatory approval of Steriwave in UAE

(Alliance News) - Ondine Biomedical Inc on Friday said it received approval to market Steriwave ...

Alliance News 18 October, 2024 | 10:27AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - Ondine Biomedical Inc on Friday said it received approval to market Steriwave in the United Arab Emirates.

The Vancouver-based company specialising in photodisinfection-based therapies said with the approval, it is able to market Steriwave nasal decolonisation to reduce healthcare-associated infections in patients undergoing surgery in the country.

Chief Executive Officer Carolyn Cross said: "We are looking forward to bringing the infection-reducing benefits of Steriwave nasal decolonization to the United Arab Emirates and other Middle Eastern Markets. We believe that adding Steriwave to current presurgical and intensive care unit protocols can help these countries to address the growing threat from antimicrobial resistant infections in hospitals."

Steriwave uses a light-activated agent to quickly eliminate infection-causing pathogens in a single five-minute treatment.

Ondine shares rose 3.9% to 6.63 pence each on Friday morning in London.

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Ondine Biomedical Inc Common Share 11.00 GBX 4.76 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures